| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 2/15/2024, p832-832, 1p |
| Abstrakt: |
Researchers at Hangzhou First People's Hospital in China have conducted a study on the treatment of hepatosplenic T-cell lymphoma (HSTCL), a difficult-to-treat form of lymphoma. The study focused on the use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with total-body irradiation (TBI) as a pretreatment regimen. Two patients with HSTCL underwent this treatment and achieved complete remission, with extended periods without disease recurrence. A systematic review of previously published cases also showed positive outcomes for patients who received allo-HSCT. The researchers concluded that this pretreatment regimen may be a viable option for young HSTCL patients undergoing allo-HSCT. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
